3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
23
INDUSTRY
2
NIH
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Myeloma
1
Lung Neoplasms
1
Interventions
pembrolizumab
302
Carboplatin
228
Cisplatin
157
Gemcitabine
155
Paclitaxel
154
Pemetrexed
122
Bevacizumab
121
Docetaxel
105
Oxaliplatin
84
durvalumab
82
Nivolumab
81
Fluorouracil
81
Dexamethasone
79
Cyclophosphamide
78
atezolizumab
77
130-nm albumin-bound paclitaxel
73
Fulvestrant
71
Capecitabine
69
Injections
65
Leucovorin
64
Cetuximab
63
Rituximab
56
Lenalidomide
52
fludarabine
51
venetoclax
46
Prednisone
45
Irinotecan
44
enzalutamide
41
Letrozole
41
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoadjuvant Therapy
×
90 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT07149857
2026-05-08
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2
Recruiting
60 enrolled